|
FY2026
12 months to Jan 31, 2026
|
FY2025
12 months to Jan 31, 2025
|
FY2024
12 months to Jan 31, 2024
|
FY2023
12 months to Jan 31, 2023
|
FY2022
12 months to Jan 31, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Income from operations | |||||
| Interest income | |||||
| Interest expense | |||||
| Other income (expense), net | |||||
| Income before income taxes | |||||
| Benefit from income taxes | |||||
| Net income | |||||
| Accretion and dividend on series A convertible preferred stock | |||||
| Undistributed earnings attributable to preferred stockholders | |||||
| Net income attributable to common stockholders | |||||
| Net income per share attributable to common stockholders, basic | |||||
| Net income per share attributable to common stockholders, diluted | |||||
| Weighted-average shares used to compute net income per share attributable to common stockholders, basic | |||||
| Weighted-average shares used to compute net income per share attributable to common stockholders, diluted | |||||
Loading...